By Ben Hirschler LONDON (Reuters) - An experimental cannabis drug has produced promising results in a small study of children with hard-to-treat epilepsy, sending shares in its British maker GW Pharmaceuticals to an all-time high. It already sells Sativex for spasticity caused by multiple sclerosis across Europe. The latest findings for its new product Epidiolex follow an assessment of 27 ...
News Source
News Source
No comments:
Post a Comment